- Home
- CGNT vs REPL Comparison
CGNT vs REPL Comparison
Compare CGNT & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGNT
- REPL
- Stock Information
- Founded
- CGNT 2020
- REPL 2015
- Country
- CGNT Israel
- REPL United States
- Employees
- CGNT N/A
- REPL N/A
- Industry
- CGNT Computer Software: Prepackaged Software
- REPL Biotechnology: Pharmaceutical Preparations
- Sector
- CGNT Technology
- REPL Health Care
- Exchange
- CGNT Nasdaq
- REPL Nasdaq
- Market Cap
- CGNT 743.4M
- REPL 851.0M
- IPO Year
- CGNT N/A
- REPL 2018
- Fundamental
- Price
- CGNT $9.95
- REPL $8.62
- Analyst Decision
- CGNT Hold
- REPL Strong Buy
- Analyst Count
- CGNT 3
- REPL 6
- Target Price
- CGNT $8.25
- REPL $20.00
- AVG Volume (30 Days)
- CGNT 389.5K
- REPL 727.0K
- Earning Date
- CGNT 04-02-2025
- REPL 05-15-2025
- Dividend Yield
- CGNT N/A
- REPL N/A
- EPS Growth
- CGNT N/A
- REPL N/A
- EPS
- CGNT N/A
- REPL N/A
- Revenue
- CGNT $350,632,000.00
- REPL N/A
- Revenue This Year
- CGNT $8.64
- REPL $31.16
- Revenue Next Year
- CGNT $9.76
- REPL N/A
- P/E Ratio
- CGNT N/A
- REPL N/A
- Revenue Growth
- CGNT 11.88
- REPL N/A
- 52 Week Low
- CGNT $6.21
- REPL $4.92
- 52 Week High
- CGNT $11.12
- REPL $17.00
- Technical
- Relative Strength Index (RSI)
- CGNT 69.45
- REPL 24.38
- Support Level
- CGNT $7.64
- REPL $10.17
- Resistance Level
- CGNT $8.49
- REPL $10.78
- Average True Range (ATR)
- CGNT 0.33
- REPL 0.65
- MACD
- CGNT 0.14
- REPL -0.24
- Stochastic Oscillator
- CGNT 86.36
- REPL 12.39
About CGNT Cognyte Software Ltd.
Cognyte Software Ltd provides security analytics software that empowers governments and enterprises with Actionable Intelligence. Its interface software is designed to help customers accelerate and improve the effectiveness of investigations and decision-making.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.